此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

2026年11月3日 更新者:Wake Forest University Health Sciences

The goal of this study is to learn whether children, adolescents, and young adults with newly diagnosed high-grade osteosarcoma can be safely discharged from the hospital at slightly higher methotrexate blood levels after receiving standard high-dose methotrexate chemotherapy. Participants are 22 years old or younger and are receiving standard MAP (high-dose methotrexate with doxorubicin and cisplatin) chemotherapy as part of their routine cancer treatment.

The main questions this study aims to answer are:

  • Is hospital discharge at higher methotrexate levels safe, based on side effects or hospital re-admission within 7 days?
  • Can patient-derived osteosarcoma tumor organoids be successfully generated across multiple centers?

Researchers will compare safety outcomes and hospital length of stay to historical patient data discharged at lower methotrexate levels.

Participants will receive standard chemotherapy, meet study-defined discharge criteria, be monitored for side effects, and have the option to provide tumor and blood samples for future research.

研究概览

详细说明

This Phase II, multi-institutional study evaluates the safety of hospital discharge at higher serum methotrexate (MTX) levels in children, adolescents, and young adults with newly diagnosed high-grade osteosarcoma receiving standard-of-care high-dose methotrexate (HD-MTX) as part of MAP chemotherapy.

Participants are discharged once they meet the pre-defined MTX clearance, kidney function, and clinical safety criteria. Methotrexate discharge thresholds are evaluated using an adaptive Bayesian threshold-finding design, starting at a serum MTX level of less than or equal to 0.15 micromolar, with possible escalation or de-escalation based on observed toxicity.

Secondary objectives include comparison of hospital length of stay and estimated inpatient costs with historical controls using traditional discharge criteria. Optional correlative studies include patient-derived osteosarcoma tumor organoids and circulating tumor cells to evaluate chemotherapy sensitivity and other future research. A separate retrospective chart review of prior patients treated with HD-MTX is included to understand safety outcomes and MTX clearance patterns.

研究类型

介入性

注册 (估计的)

46

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • 尚未招聘
        • University of North Carolina at Chapel Hill
        • 接触:
        • 首席研究员:
          • Ian Davis, MD, PhD
      • Charlotte、North Carolina、美国、28203
        • 招聘中
        • Atrium Health Levine Children's Hospital
        • 首席研究员:
          • Thomas Russell, MD
        • 接触:
      • Charlotte、North Carolina、美国、28204
        • 尚未招聘
        • Novant Health Hemby Children's Hospital
        • 首席研究员:
          • Jessica Bell, MD
        • 接触:
      • Durham、North Carolina、美国、27710
        • 尚未招聘
        • Duke University Medical Center
        • 首席研究员:
          • Jessica Sun, MD
        • 接触:
      • Greenville、North Carolina、美国、27834
        • 尚未招聘
        • East Carolina University
        • 接触:
        • 首席研究员:
          • Andrea Whitfield, DO
      • Winston-Salem、North Carolina、美国、27157
        • 招聘中
        • Atrium Health Wake Forest Baptist
        • 首席研究员:
          • Sarah Supples, MD
        • 接触:
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 尚未招聘
        • Medical University of South Carolina
        • 首席研究员:
          • Jacqueline Kraveka, DO
        • 接触:
      • Columbia、South Carolina、美国、29203
        • 尚未招聘
        • Prisma Health Midlands
        • 接触:
        • 首席研究员:
          • Chandni Dargan, MD
      • Greenville、South Carolina、美国、29605
        • 尚未招聘
        • Prisma Health Upstate
        • 首席研究员:
          • Chandni Dargan, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

7年 至 22年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Pre-Enrollment Criteria:

  1. Suspected diagnosis of high-grade osteosarcoma based on clinical and radiographic findings.
  2. Informed consent (and assent, if applicable) obtained, per institutional guidelines.
  3. Participants must be ≤ 22 years of age at the time of consent.

Inclusion Criteria:

  1. Participants with localized or metastatic high-grade osteosarcoma.

  2. Participants must be ≤ 22 years of age at the time of consent.

  3. Participants must have a body surface area of greater than or equal to 0.8 m2.

  4. Participants receiving or planning to receive induction/neoadjuvant MAP chemotherapy with HD-MTX given at the standard dose of 12 gm/m2 (maximum 20 gm).

    NOTE: Participants may be participating on other clinical studies such as the COG trial AOST2032 or any other clinical trial as long as their treatment includes MAP chemotherapy with the standard HD-MTX dose of 12 gm/m2 (maximum 20 gm).

  5. Participants may receive other chemotherapy agents in their treatment provided that drug(s) are not known to interfere with HD-MTX clearance when given concurrently. Medications known to interfere with HD-MTX clearance are listed in Appendix A.

  6. Participants must meet minimum organ function requirements to receive HD-MTX:

    • Adequate liver function defined as: total bilirubin ≤ 1.5x upper limit of normal (ULN) for age at the time of consent and alanine aminotransferase (ALT/SGPT) ≤ 135 U/L for age at the time of consent.
    • Adequate renal function defined as: a serum creatinine based on age/gender OR - a 24-hour urine Creatinine clearance ≥ 70 mL/min/1.73 m2, OR - an estimated glomerular filtration rate (GFR) of greater than or equal to 70 mL/min/1.73 m2 for age at the time of consent.
    • Adequate bone marrow function defined as: peripheral absolute neutrophil count (ANC) ≥ 1000/µL, platelet count ≥ 100,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment), and hemoglobin ≥ 8.0 g/dL (transfusion independent, defined as not receiving red blood cell transfusions within a 7-day period prior to enrollment)
  7. Adequate cardiac function, defined as a left ventricular ejection fraction (LVEF) ≥ 50%, assessed per institutional standard of care using non-invasive imaging modalities such as a Multi-Gated Acquisition (MUGA) scan or echocardiogram (echo).

    NOTE: Cardiac function assessment will be performed as part of routine clinical care. No additional imaging or procedures will be mandated by the research protocol.

  8. Informed consent, and assent when appropriate, must be obtained, per institutional guidelines.

  9. Participants can enroll after initiation of induction MAP chemotherapy so long as they are enrolled prior to the second cycle of chemotherapy (prior to week 6 cisplatin and doxorubicin).

  10. Participants must be willing and able to comply with all study procedures for the entire length of the study.

Exclusion Criteria:

  1. Female participants who are pregnant and/or lactating and breast feeding their infant(s).

    NOTE: Pregnancy testing will follow institutional standard of care practice and is not mandated by the protocol.

  2. Sexually active participants of reproductive potential who have not agreed to use an effective contraceptive method for the duration of protocol therapy, at the discretion of the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Standard-of-Care MAP Chemotherapy with Threshold-Adjusted HD-MTX Discharge

Participants with newly diagnosed high-grade osteosarcoma receive standard-of-care MAP chemotherapy, including high-dose methotrexate (HD-MTX), with hospital discharge based on serum methotrexate threshold levels (ranging from ≤0.10 µM to ≤0.20 µM) and renal function criteria to evaluate the safety of earlier discharge. Threshold levels are not randomized and are evaluated sequentially over the course of the study.

High-dose methotrexate (HD-MTX) is administered intravenously at a dose of 12 g/m² (maximum dose 20 g) over 4 hours as part of standard-of-care MAP chemotherapy for participants with newly diagnosed high-grade osteosarcoma. HD-MTX is delivered with standard supportive care measures, including alkalinized intravenous hydration, serial serum methotrexate level monitoring, and leucovorin rescue beginning 24 hours after methotrexate initiation and continued until discharge criteria are met. Treatment is administered according to institutional standards throughout neoadjuvant/induction and adjuvant/consolidation therapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Dose Limiting Toxicity (DLT)
大体时间:Within 7-days post-discharge of methotrexate visit

A binary response for dose-limiting toxicity following MTX visit discharge defined as rehospitalization due to acute toxicity or serious adverse event of special interest

Within 7-days post-discharge of methotrexate visit

次要结果测量

结果测量
措施说明
大体时间
Length of Stay (LOS)
大体时间:From time of admission to time of discharge in hours for each HD-MTX inpatient cycle, assessed across [up to] 12 cycles per participant, through completion of HD-MTX therapy (up to approximately 30 weeks per participant from first week of treatment)

Length of hospital stay measured in hours from time of admission to time of discharge for each HD-MTX inpatient cycle

From time of admission to time of discharge in hours for each HD-MTX inpatient cycle, assessed across [up to] 12 cycles per participant, through completion of HD-MTX therapy (up to approximately 30 weeks per participant from first week of treatment)
Patient Cost Per Visit
大体时间:Approximately 30 weeks per participant from first week of treatment

Total estimated cost associated with each HD-MTX inpatient cycle, based on hospital billing charges and nights of stay

Approximately 30 weeks per participant from first week of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Thomas Russell, MD、Alliance for Research and Innovations in Pediatric Oncology (ARISE) Cancer Consortium

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月31日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年4月16日

首先提交符合 QC 标准的

2026年4月23日

首次发布 (实际的)

2026年5月1日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • Pro00081644
  • ARISE-CATSINDO (其他标识符:Alliance for Research and Innovations in Pediatric Oncology (ARISE) Cancer Consortium)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅